Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cardiovascular Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,059 result(s) found for: Cardiovascular Disease. Displaying page 1 of 103.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2018-001917-34 Sponsor Protocol Number: TropO2 Start Date*: 2018-12-14
    Sponsor Name:Consorci Mar Parc de Salut de Barcelona
    Full Title: Cardiac complications associated to perioperative hyperoxia in elective colorectal surgery
    Medical condition: Cardiovascular complications after colorectal surgery
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    20.0 100000004865 10050322 Oxygen supplementation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012269-71 Sponsor Protocol Number: BC22140 Start Date*: 2010-03-08
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: Cardiovascular outcomes study to evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event and type 2 diabetes mellitus (T2D)
    Medical condition: Type 2 diabetes patients with a recent acute coronary syndrome (ACS) event
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10007649 Cardiovascular disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Temporarily Halted) SE (Prematurely Ended) DK (Prematurely Ended) FR (Completed) IE (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001891-21 Sponsor Protocol Number: NC25608 Start Date*: 2012-02-21
    Sponsor Name:F.Hoffmann-La Roche Ltd
    Full Title: A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients with Stable Coronary H...
    Medical condition: Patients with stable CHD, CHD risk equivalents (including PAD, cerebrovascular disease, and T2D), or at elevated risk for CV mortality and morbidity on the basis of multiple risk factors for CVD by...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10007649 Cardiovascular disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) PL (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) GB (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-007638-21 Sponsor Protocol Number: CR2 Start Date*: 2008-09-04
    Sponsor Name:University of Aberdeen [...]
    1. University of Aberdeen
    2. NHS Grampian Health Board
    Full Title: Is cessation of clopidogrel therapy associated with rebound of platelet activity in stable vascular disease patients?
    Medical condition: Cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10035523 Platelet analyses HLT
    9.1 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-006875-35 Sponsor Protocol Number: HMARAAS1 Start Date*: 2009-10-27
    Sponsor Name:IMAS
    Full Title: Administración perioperatoria de aspirina a baja dosis como prevención secundaria de muerte súbita, apoplejía, infarto de miocardio y otros accidentes isquémicos postoperatorios. Ensayo clínico mul...
    Medical condition: Paciente con indicación quirúrgica electiva de riesgo cardiovascular intermedio (cirugía oncológica con apertura del abdomen y/o tórax como, artroplastia de cadera o rodilla) y que esté recibiendo ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002257-19 Sponsor Protocol Number: CARDIORYC-2014-001 Start Date*: 2015-04-21
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital Ramón y Cajal
    Full Title: Single-center, randomized, open, controlled by echocardiography to evaluate the effect of serelaxina in the functioning of the right ventricle and its potential in the prognosis of acute heart fail...
    Medical condition: ICA hospitalized patients with high normal blood pressure, and mild to moderate renal failure at the time of selection
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022641-25 Sponsor Protocol Number: MASTER2010 Start Date*: 2011-07-11
    Sponsor Name:University Medical Center Utrecht
    Full Title: Maraviroc Abacavir STudy – effect on Endothelial Recovery
    Medical condition: -Human Imunodeficiency Virus (HIV) infection -Endothelial dysfunction in HIV-infected patients -immune activation in HIV-infected patients -cardiovascular complications in HIV-infecetd patients
    Disease: Version SOC Term Classification Code Term Level
    12.1 10008919 Chronic HIV infection LLT
    12.1 10008922 Chronic infection with HIV LLT
    12.1 10048554 Endothelial dysfunction LLT
    12.1 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005532-32 Sponsor Protocol Number: KWI-NIC-02 Start Date*: 2009-03-13
    Sponsor Name:Kwizda Pharma
    Full Title: The bioavailability of nicorandil in humans: A pilot study to investigate the variability of its pharmacokinetic parameters in healthy volunteers.
    Medical condition: The bioavailability of Nicorandil in humans: A pilot study to investigate the variability of the pharmacokinetic parameters in healthy volunteers. The IMP Nicorandil (2-(pyridine-3-carbonylamino)et...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007649 Cardiovascular disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012270-12 Sponsor Protocol Number: BC22419 Start Date*: 2010-05-21
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: Effects of 150 μg aleglitazar on renal function in patients with Type 2 diabetes and moderate renal impairment, as compared to Actos®
    Medical condition: Type 2 diabetes with moderate renal function impairment
    Disease: Version SOC Term Classification Code Term Level
    12.0 10007649 Cardiovascular disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000215-89 Sponsor Protocol Number: CL2-16257-099 Start Date*: 2013-06-14
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Effects of ivabradine on vascular function in individuals at increased risk of developing cardiovascular disease and with impaired endothelial function An international, multicentre, randomised, d...
    Medical condition: Cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) GB (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001076-11 Sponsor Protocol Number: CTQJ230A12301 Start Date*: 2019-12-19
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with establishe...
    Medical condition: Cardiovascular Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10051614 Arteriosclerotic cardiovascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Restarted) AT (Ongoing) GB (GB - no longer in EU/EEA) DK (Ongoing) SK (Ongoing) IT (Ongoing) GR (Ongoing) PT (Ongoing) SE (Ongoing) NL (Ongoing) BG (Ongoing) BE (Ongoing) NO (Ongoing) SI (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001743-31 Sponsor Protocol Number: NL43882.029.13 Start Date*: 2013-08-06
    Sponsor Name:VU University Medical Center
    Full Title: The cardiovascular effects of hyperoxia during and shortly after CABG surgery
    Medical condition: During and after coronary artery bypass graft operation we will investigate the cardiovascular effects of hyperoxia on blood pressure, cardiac function, microcirculation and ischemia/reperfusion.
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003946-34 Sponsor Protocol Number: OB-401 Start Date*: 2013-10-30
    Sponsor Name:VIVUS, Inc.
    Full Title: A Qsymia™ CardiovascuLAr morbIdity and Mortality (AQCLAIM) Study in Subjects with Documented Cardiovascular Disease
    Medical condition: Cardiovascular Disease in overweight and obese subjects
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Prematurely Ended) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-002006-27 Sponsor Protocol Number: CKJX839B12302 Start Date*: 2021-11-15
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, placebo -controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease...
    Medical condition: Atherosclerotic cardiovascular disease (ASCVD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) SK (Ongoing) PT (Ongoing) LT (Ongoing) NL (Ongoing) IT (Ongoing) AT (Ongoing) LV (Ongoing) HU (Ongoing) SE (Ongoing) DK (Ongoing) SI (Ongoing) BG (Ongoing) HR (Ongoing) NO (Ongoing) PL (Ongoing) FI (Ongoing) GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006922-32 Sponsor Protocol Number: HOADO Start Date*: 2009-02-09
    Sponsor Name:RUNMC
    Full Title: Heme oxygenase (HO) activity in humans. Effects of heme arginate (Normosang®) on parameters of HO activity and on adenosine induced vasodilation.
    Medical condition: Normosang treatment will be used to evaluate heme oxygenase induction in healthy subjects. Results will be used for future studies concerning diabetes related cardiovascular disease.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051615 Atherosclerotic cardiovascular disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001069-18 Sponsor Protocol Number: 12/0533 Start Date*: 2013-07-11
    Sponsor Name:University College London (UCL)
    Full Title: MINeralocorticoid receptor antagonist pretreatment to MINIMISE reperfusion injury after ST-Elevation Myocardial Infarction(STEMI).
    Medical condition: Cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10007649 Cardiovascular disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-002466-35 Sponsor Protocol Number: ACTRN012607000099426 Start Date*: 2008-03-11
    Sponsor Name:Imperial Ciollege [...]
    1. Imperial Ciollege
    2. St Mary's NHS Trust
    3. University Medical Center Utrecht
    Full Title: A randomised placebo-controlled trial of fixed-dose combination medication in those at raised risk of cardiovascular disease
    Medical condition: Cardiovascular Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003000-39 Sponsor Protocol Number: CL2-38844-010 Start Date*: 2014-03-20
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Evaluation of the pharmacodynamics, pharmacokinetics and safety of repeated escalating oral doses of S 38844 versus placebo in patients with chronic heart failure and left ventricular systolic d...
    Medical condition: Patients with chronic heart failure and left ventricular systolic dysfunction
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) SK (Completed) EE (Completed) LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2022-001682-12 Sponsor Protocol Number: MYOFLAME-19 Start Date*: 2023-06-16
    Sponsor Name:Goethe University Frankfurt
    Full Title: Randomised placebo controlled clinical trial of efficacy of MYOcardial protection in patients with postacute inFLAMmatory cardiac involvEment due to COVID-19 (MYOFLAME-19)
    Medical condition: Inflammatory cardiovascular involvement due to COVID-19, defined by Cardiovascular magnetic resonance imaging
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    20.0 100000004849 10007650 Cardiovascular disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005288-33 Sponsor Protocol Number: EMI111784 Start Date*: 2008-12-18
    Sponsor Name:GlaxoSmithKline Research & Development, LtdD
    Full Title: Methodology Study to develop Sinerem enhanced 3T MR Imaging of Atherosclerotic Plaques within the Carotid Arteries, and to compare Sinerem MRI to contrast enhanced ultrasound
    Medical condition: Atherosclerotic plaque within the carotid artery.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051615 Atherosclerotic cardiovascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 02 07:03:54 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA